(Oslo Bors:EQNR),(Oslo Bors:EQNR01), Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 30 April 2025 a cash dividend per share of USD 0.37 for first quarter 2025. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 19 August 2025, […]

Equinor ASA: Announcement of cash dividend of NOK 3.7740 per share for first quarter 2025 GlobeNewswire August 25, 2025 Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 30 April 2025 a cash dividend per share of USD 0.37 for first quarter 2025. The NOK cash dividend per share is based on average USDNOK fixing rate

Akeso Inc. (9926.HK) (“Akeso” or “the Company”) today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study successfully met all primary efficacy endpoints, including ASAS20 and subgroup analyses, as well as the key secondary endpoint

Manulife Hong Kong and Macau are pleased to announce three senior leadership appointments that underscore its commitment to executing strategic priorities and accelerating business growth. Danny Lee has been named Chief Health Officer, KC Cheung as Chief Product Officer, and Louisa Li as Chief Strategy Officer and Head of Macau Branch. These appointments reflect the

This is a report from China.org.cn: Generation Z has become a transformative force in China's consumer market. Unlike previous generations, their spending priorities emphasize individual and social well-being, driving a surge in what analysts call “emotional consumption.” The trend – fueled by demand for self-care products, experiences and collectibles – is reshaping the domestic market

(Paris:OSE), OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting New Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi(R) and Lusvertikimab Nantes, August 25, 2025, 7:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual

(Paris:VLA),(Paris:VLAP), Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ(R), citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is

(Brussels:ARGX),(NASDAQ:ARGX), Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to be submitted to U.S. Food and Drug Administration (FDA) by end of 2025 August 25, 2025, 7:00 AM CET Amsterdam, the

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting GlobeNewswire August 25, 2025 OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting New Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi(R) and Lusvertikimab Nantes, August 25, 2025,

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ(R) in the U.S. GlobeNewswire August 25, 2025 Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ(R), citing four